Gamida Cell Ltd.'s NiCord® Demonstrates Successful Engraftment in Patients With Hematological Malignancies in Phase I/II Study
2/15/2013 9:17:49 AM
JERUSALEM--(BUSINESS WIRE)--Gamida Cell announced today the successful results of the Phase I/II study of its second pipeline product NiCord, umbilical cord derived stem cells expanded using the company’s proprietary NAM technology. Study data was announced today during an oral presentation titled Nicord® Expanded Hematopoietic Progenitor Cells (HPC) Are Capable of Outcompeting the Unmanipulated (UM) Cord Blood Unit and of Prolonged Myeloid and Lymphoid Engraftment Following Myeloablative Dual Umbilical Cord Blood (UCB) Transplantation. The presentation was delivered at the prestigious 2013 BMT Tandem Meetings in Salt Lake City by Dr. Mitchell E. Horwitz, associate professor of medicine at Duke Medicine and a principal investigator of the NiCord study for hematological malignancies (HM).